A Phase 3 Double-blind Placebo-controlled Randomized Study to Assess the Efficacy and Safety of Epicutaneous Immunotherapy with DBV712 250 g in 4-7-year-old Children with Peanut Allergy

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Peanut Allergy
  • Age: Between 4 Year(s) - 7 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Age: Between 4-7 years
    2. Gender: Male or Female
    3. Physician-diagnosed peanut allergy
    4. Currently following a strict peanut-free diet
    5. Serum peanut-specific IgE > 0.7 kUA/L and a positive peanut skin prick test

You may not be eligible for this study if the following are true:

    1. You are participating in current immunotherapy for any allergen (including food allergy, allergic rhinitis and/or insect allergy)
    2. Past history of very severe anaphylaxis to peanut
    3. Inability to stop short-acting or long-acting antihistamines for a minimum washout period
    4. Diagnosed with poorly or uncontrolled asthma
    5. Have a history of any immunotherapy for peanut allergy, including EPIT, OIT, SLIT



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.